Gilead Sciences (GILD) 106.45 $GILD
Final Glance: Biotechnology companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
Shares of AMAG (AMAG) soared 28.2% after it announced that it will be acquiring privately held Lumara.
Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
Midday Glance: Biotechnology companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
Early Glance: Biotechnology companies
AP - Tue Sep 30, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
at The Street - Tue Sep 30, 8:49AM CDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 8:46AM CDT
Ambit Biosciences (AMBI) was a big mover last session, with shares surging over 87% on the day.
Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 8:39AM CDT
Immunomedics Inc. (IMMU) was a big mover last session, as its shares rose over 9% on the day.
Gilead Sciences, Inc. Stock's Stunning New Opportunity
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Sep 30, 8:15AM CDT
Call it Gilead Sciences ' stealth play. Gilead is the king of the HIV business. Its wildly successful Sovaldi launch is without a doubt the biggest biotech event of the year. But the company's experimental cancer drug pipeline is a different...
Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:51AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session, as its shares rose over 13% on the day.
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher
PR Newswire - Tue Sep 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Thermo Fisher Scientific, Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6854-100free.
Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:36AM CDT
Raptor Pharmaceuticals (RPTP) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down over 11% since Sep 11.
Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 5:50PM CDT
A response from the FDA on Bristol-Myers' (BMY) Opdivo should be out by Mar 30.
Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:55PM CDT
Alimera Sciences, Inc.'s (ALIM) announced that the FDA has approved Iluvien for the long-term treatment of diabetic macular edema (DME).
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
Gilead's HCV Combo Drug Harvoni Secures CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:20PM CDT
Gilead's Harvoni is recommended for approval in the EU.
Nektar/AstraZeneca's Moventig a Step Closer to EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:10PM CDT
Nektar (NKTR) and AstraZeneca's (AZN) Moventig is one step closer to receiving EU approval.
Gilead Sciences (GILD) Breaks Through Support at $107.09
Comtex SmarTrend(R) - Mon Sep 29, 9:04AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $108.05 today and has reached the first level of support at $107.09. Analysts will be watching for a cross of the next downside pivot targets of $105.80 and $103.55.
Final Glance: Biotechnology companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
Shares of AMAG (AMAG) soared 28.2% after it announced that it will be acquiring privately held Lumara.
Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
Midday Glance: Biotechnology companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
Early Glance: Biotechnology companies
AP - Tue Sep 30, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
at The Street - Tue Sep 30, 8:49AM CDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 8:46AM CDT
Ambit Biosciences (AMBI) was a big mover last session, with shares surging over 87% on the day.
Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 8:39AM CDT
Immunomedics Inc. (IMMU) was a big mover last session, as its shares rose over 9% on the day.
Gilead Sciences, Inc. Stock's Stunning New Opportunity
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Sep 30, 8:15AM CDT
Call it Gilead Sciences ' stealth play. Gilead is the king of the HIV business. Its wildly successful Sovaldi launch is without a doubt the biggest biotech event of the year. But the company's experimental cancer drug pipeline is a different...
Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:51AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session, as its shares rose over 13% on the day.
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher
PR Newswire - Tue Sep 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Thermo Fisher Scientific, Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6854-100free.
Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:36AM CDT
Raptor Pharmaceuticals (RPTP) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down over 11% since Sep 11.
Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 5:50PM CDT
A response from the FDA on Bristol-Myers' (BMY) Opdivo should be out by Mar 30.
Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:55PM CDT
Alimera Sciences, Inc.'s (ALIM) announced that the FDA has approved Iluvien for the long-term treatment of diabetic macular edema (DME).
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
Gilead's HCV Combo Drug Harvoni Secures CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:20PM CDT
Gilead's Harvoni is recommended for approval in the EU.
Nektar/AstraZeneca's Moventig a Step Closer to EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:10PM CDT
Nektar (NKTR) and AstraZeneca's (AZN) Moventig is one step closer to receiving EU approval.
Gilead Sciences (GILD) Breaks Through Support at $107.09
Comtex SmarTrend(R) - Mon Sep 29, 9:04AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $108.05 today and has reached the first level of support at $107.09. Analysts will be watching for a cross of the next downside pivot targets of $105.80 and $103.55.
